Aerie Pharmaceuticals, Inc. operates as a pharmaceutical enterprise focused on the discovery, development, and commercialization of ophthalmic treatments for the U.S. market. The company's therapeutic scope includes open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration. Its commercialized portfolio features Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure (IOP) for patients with open-angle glaucoma or ocular hypertension. Also available is Rocklatan, a daily fixed-dose combination of Rhopressa and latanoprost, which similarly works to reduce IOP in individuals with these conditions. In its development pipeline, Aerie is advancing AR-15512 to address the symptoms and signs of dry eye, alongside AR-1105 and AR-14034 SR, which are sustained-release implants targeting various retinal diseases. The company also engages in a collaborative research, development, and licensing agreement with DSM Biomedical. Established in 2005, Aerie Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.